About GHK-Cu Pharmacy: who reads the literature here, and who does not.

What this site is

GHK-Cu Pharmacy reads the peer-reviewed literature on GHK-Cu — the copper(II) complex of glycyl-histidyl-lysine — and sets it out one scene at a time: the fibroblast dose-response work, the human hair trial, the copper-stability chemistry, the gene-expression analyses, and the regulatory line. Every quantitative claim is tied to the study it came from, and the thin or absent evidence is shown as plainly as the strong.

Think of it as a reading bench rather than a counter. Nothing on these pages is manufactured, stocked, sold, dispensed, or prescribed, and no clinician, pharmacist, or health-advice service stands behind the name. The pages are a commentary on published science for readers who want the record in plain language and cited honestly — never a diagnosis, a dose, or a suggestion to use anything.

Why 'Pharmacy' is in the name

The word 'Pharmacy' here is editorial framing, not a description of services. It signals the position this publisher takes toward the literature: the careful, label-reading, dose-and-route-aware posture a pharmacy is associated with — applied to a reading of the record, not to dispensing. No prescriptions are written, filled, or implied on this site, and nothing is for sale. We hold that posture precisely because the GHK-Cu record rewards it: the safety story turns on copper-binding chemistry and the gap between topical and systemic evidence, which is exactly the kind of distinction a careful reading is built to keep straight ^[8].

How we handle the evidence

We lead with what was measured and attribute it after. When a finding is a controlled human trial, we say so; when it is in vitro, rodent, or bioinformatic, we say that too. We preserve the difference between GHK and GHK-Cu because copper coordination changes the result ^[3]. We flag the limits the literature flags — the single-investigator concentration of foundational work, the absence of validated human pharmacokinetics for systemic use, and the null objective endpoints alongside the positive ones ^[9][16]. The aim is a digest a skeptical reader can trust because the gaps are visible, not hidden.

What the digest covers

The scope is the published GHK-Cu record across its main territories: the fibroblast collagen dose-response and broader skin remodeling ^[1][3], the copper-handling and antioxidant chemistry that bounds the safety question ^[8], the controlled human hair trial and its preclinical basis ^[4][13], the gene-expression signature and its caveats ^[2], and the regulatory line between topical cosmetic use and unapproved systemic use ^[10]. Each claim on the site carries a bracketed marker that resolves to a numbered source, so the digest can be read forwards as a narrative or sideways as a citation index. When the literature updates — a new delivery study, a registered trial that reads out — the record here is meant to be corrected, not frozen.